Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Treace Medical Concepts, Inc.NASDAQ: TMCI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $899K fell 63.5% year over year, behind the +0.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 68.8% from the prior quarter. Over 3 fiscal years it compounded at +70.1% a year.
Context
- Depreciation & amortization amounted to 4.9% of revenue in FY2025, up 0.9 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -63.5% toward the trailing-twelve-month pace of +0.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 10.5M USD
- Year-over-year change
- +24.7%
- 4-year CAGR
- +97.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.5M | +24.7% |
| FY2024 | 2024-12-31 | 8.42M | +57.3% |
| FY2023 | 2023-12-31 | 5.35M | +150.9% |
| FY2022 | 2022-12-31 | 2.13M | +211.4% |
| FY2021 | 2021-12-31 | 685K | — |
Depreciation & Amortization vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's LTM Mar 2026 depreciation & amortization of $9.02M is the 5th largest of the 8 companies compared; the peer median is $9.61M.
- Its year-over-year change of +0.5% is the 4th highest of 8, against a peer median of -6.6%.
- Depreciation & amortization amounts to 4.4% of revenue for TMCI, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $46.35M | -6.6% | -5.3% | 8.0% | |
| LTM Mar 2026 | $21.79M | +14.1% | +17.3% | 9.0% | |
| LTM Mar 2026 | $10.99M | -30.6% | -51.5% | 12.7% | |
| LTM Mar 2026 | $9.61M | +52.7% | +24.8% | 3.2% | |
| LTM Mar 2026 | $9.02M | +0.5% | +70.1% | 4.4% | |
| LTM Mar 2026 | $3.32M | +1.4% | -6.7% | 2.6% | |
| LTM Mar 2026 | $3.25M | -50.6% | +16.3% | 0.6% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $640K | -47.5% | — | 0.7% |
| Peer median (excluding TMCI) | $9.61M | -6.6% | +5.5% | 3.2% | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Depreciation & Amortization | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| Deferred Income Tax | 419K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.41M | 8.11M | 17.35M | 30.6M | 33.82M |
| Change in Working Capital | (1.33M) | (5.81M) | (9.74M) | (25.43M) | (8.58M) |
| Accounts Receivables | (4.23M) | (11.04M) | (9.3M) | (5.69M) | (2.09M) |
| Inventory | (3.09M) | (8.77M) | (9.85M) | (10.01M) | 3.22M |
| Accounts Payables | 1.79M | 4.61M | 3.17M | (1.31M) | (3.8M) |
| Other Working Capital | 4.19M | 9.39M | 6.24M | (8.42M) | (5.92M) |
| Other Non-Cash Items | 176K | 7.73M | 1.99M | 4.99M | 7.29M |
| Operating Cash Flow | (17.19M) | (30.65M) | (34.58M) | (37.17M) | (15.97M) |
| Capital Expenditures | (2.71M) | (14.84M) | (11.46M) | (11.59M) | (13.52M) |
| Acquisitions (Net) | 0 | 61.68M | (20M) | 0 | 0 |
| Purchases of Investments | 0 | (63.41M) | (169.87M) | (71.58M) | (40.57M) |
| Sales of Investments | 0 | 1.73M | 120.02M | 118.55M | 67.34M |
| Other Investing Activities | 0 | (61.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (2.71M) | (76.52M) | (81.3M) | 35.38M | 13.25M |
| Debt Repayment | (1.79M) | 19.61M | 0 | 0 | 2.43M |
| Common Stock Issued | 109.44M | 2.19M | 109.4M | 428K | 546K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (989K) | (13K) | (268K) | (902K) |
| Financing Cash Flow | 107.65M | 20.81M | 109.38M | 160K | 2.08M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 87.75M | (86.36M) | (6.49M) | (1.63M) | (642K) |
| Free Cash Flow | (19.9M) | (45.49M) | (46.03M) | (48.76M) | (29.49M) |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.